icr.ac.uk8d
The Adult Drug Development Unit at the ICR and the RM
The Adult Drug Development Unit (DDU) at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, comprises an internationally-leading group of >100 staff focused on early ...
icr.ac.uk11d
Newly identified therapeutic target may lead to effective treatments for the most common and dangerous form of brain cancer
Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma, a common type of adult brain tumour, rely on a specific enzyme for survival and that inhibiting ...
icr.ac.uk9d
Unlocking the potential of protein degradation in cancer research
Dr Agnieszka Konopacka recently joined The Institute of Cancer Research, London, as Group Leader of the Induced Proximity Therapeutics Group, which sits within the Centre for Protein Degradation in ...
icr.ac.uk7d
Finding a way to drug the rare cancer that killed my mother
Professor Paul Workman was 37 and already well established as a cancer researcher when his mother, Ena, died aged 68 from a rare bone tumour known as chordoma. About one in a million people are ...
icr.ac.uk9d
Preclinical Molecular Imaging Group
Dr Gabriela Kramer-Marek’s group uses cutting-edge biomedical imaging techniques to gain information about the way particular genes drive cancer progression. Our group’s long-term goal is to develop ...